Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review

Increasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in...

Full description

Bibliographic Details
Main Authors: Byeongsang Oh, Frances Boyle, Nick Pavlakis, Stephen Clarke, Alex Guminski, Thomas Eade, Gillian Lamoury, Susan Carroll, Marita Morgia, Andrew Kneebone, George Hruby, Mark Stevens, Wen Liu, Brian Corless, Mark Molloy, Towia Libermann, David Rosenthal, Michael Back
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.706331/full
id doaj-55fe88a7821b4413912e926930a2d51c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Byeongsang Oh
Byeongsang Oh
Byeongsang Oh
Byeongsang Oh
Frances Boyle
Frances Boyle
Nick Pavlakis
Nick Pavlakis
Stephen Clarke
Stephen Clarke
Alex Guminski
Alex Guminski
Alex Guminski
Thomas Eade
Thomas Eade
Thomas Eade
Gillian Lamoury
Gillian Lamoury
Gillian Lamoury
Susan Carroll
Susan Carroll
Susan Carroll
Marita Morgia
Marita Morgia
Andrew Kneebone
Andrew Kneebone
Andrew Kneebone
George Hruby
George Hruby
George Hruby
Mark Stevens
Mark Stevens
Wen Liu
Brian Corless
Mark Molloy
Towia Libermann
Towia Libermann
David Rosenthal
Michael Back
Michael Back
Michael Back
spellingShingle Byeongsang Oh
Byeongsang Oh
Byeongsang Oh
Byeongsang Oh
Frances Boyle
Frances Boyle
Nick Pavlakis
Nick Pavlakis
Stephen Clarke
Stephen Clarke
Alex Guminski
Alex Guminski
Alex Guminski
Thomas Eade
Thomas Eade
Thomas Eade
Gillian Lamoury
Gillian Lamoury
Gillian Lamoury
Susan Carroll
Susan Carroll
Susan Carroll
Marita Morgia
Marita Morgia
Andrew Kneebone
Andrew Kneebone
Andrew Kneebone
George Hruby
George Hruby
George Hruby
Mark Stevens
Mark Stevens
Wen Liu
Brian Corless
Mark Molloy
Towia Libermann
Towia Libermann
David Rosenthal
Michael Back
Michael Back
Michael Back
Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
Frontiers in Oncology
gut microbiome
chemotherapy
cancer
biomarker
adverse events
author_facet Byeongsang Oh
Byeongsang Oh
Byeongsang Oh
Byeongsang Oh
Frances Boyle
Frances Boyle
Nick Pavlakis
Nick Pavlakis
Stephen Clarke
Stephen Clarke
Alex Guminski
Alex Guminski
Alex Guminski
Thomas Eade
Thomas Eade
Thomas Eade
Gillian Lamoury
Gillian Lamoury
Gillian Lamoury
Susan Carroll
Susan Carroll
Susan Carroll
Marita Morgia
Marita Morgia
Andrew Kneebone
Andrew Kneebone
Andrew Kneebone
George Hruby
George Hruby
George Hruby
Mark Stevens
Mark Stevens
Wen Liu
Brian Corless
Mark Molloy
Towia Libermann
Towia Libermann
David Rosenthal
Michael Back
Michael Back
Michael Back
author_sort Byeongsang Oh
title Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
title_short Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
title_full Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
title_fullStr Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
title_full_unstemmed Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review
title_sort emerging evidence of the gut microbiome in chemotherapy: a clinical review
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-09-01
description Increasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “chemotherapy” and “microbiome/microbiota”. The relevant literature was selected for use in this article. Seventeen studies were selected on participants with colorectal cancer (CRC; n=5), Acute Myeloid Leukemia (AML; n=3), Non-Hodgkin’s lymphoma (n=2), breast cancer (BCa; n=1), lung cancer (n=1), ovarian cancer (n=1), liver cancer (n=1), and various other types of cancers (n=3). Seven studies assessed the relationship between the gut microbiome and CTX with faecal samples collected prior to (n=3) and following CTX (n=4) showing that the gut microbiome is associated with both CTX efficacy and toxicity. Ten other prospective studies assessed the impact of CTX during treatment and found that CTX modulates the gut microbiome of people with cancer and that dysbiosis induced by the CTX is related to AEs. CTX adversely impacts the gut microbiome, inducing dysbiosis and is associated with CTX outcomes and AEs. Current evidence provides insights into the gut microbiome for clinicians, cancer survivors and the general public. More research is required to better understand and modify the impact of CTX on the gut microbiome.
topic gut microbiome
chemotherapy
cancer
biomarker
adverse events
url https://www.frontiersin.org/articles/10.3389/fonc.2021.706331/full
work_keys_str_mv AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT byeongsangoh emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT francesboyle emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT francesboyle emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT nickpavlakis emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT nickpavlakis emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT stephenclarke emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT stephenclarke emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT alexguminski emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT alexguminski emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT alexguminski emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT thomaseade emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT thomaseade emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT thomaseade emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT gillianlamoury emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT gillianlamoury emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT gillianlamoury emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT susancarroll emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT susancarroll emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT susancarroll emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT maritamorgia emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT maritamorgia emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT andrewkneebone emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT andrewkneebone emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT andrewkneebone emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT georgehruby emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT georgehruby emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT georgehruby emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT markstevens emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT markstevens emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT wenliu emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT briancorless emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT markmolloy emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT towialibermann emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT towialibermann emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT davidrosenthal emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT michaelback emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT michaelback emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
AT michaelback emergingevidenceofthegutmicrobiomeinchemotherapyaclinicalreview
_version_ 1717378392162041856
spelling doaj-55fe88a7821b4413912e926930a2d51c2021-09-16T04:37:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.706331706331Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical ReviewByeongsang Oh0Byeongsang Oh1Byeongsang Oh2Byeongsang Oh3Frances Boyle4Frances Boyle5Nick Pavlakis6Nick Pavlakis7Stephen Clarke8Stephen Clarke9Alex Guminski10Alex Guminski11Alex Guminski12Thomas Eade13Thomas Eade14Thomas Eade15Gillian Lamoury16Gillian Lamoury17Gillian Lamoury18Susan Carroll19Susan Carroll20Susan Carroll21Marita Morgia22Marita Morgia23Andrew Kneebone24Andrew Kneebone25Andrew Kneebone26George Hruby27George Hruby28George Hruby29Mark Stevens30Mark Stevens31Wen Liu32Brian Corless33Mark Molloy34Towia Libermann35Towia Libermann36David Rosenthal37Michael Back38Michael Back39Michael Back40Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaUniversity of Kansas Medical Center, Kansas City, KS, United StatesCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaUniversity of Kansas Medical Center, Kansas City, KS, United StatesNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaBowel Cancer and Biomarker Laboratory, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaBeth Israel Deaconess Medical Center (BIDMC) Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Boston, MA, United StatesHarvard Medical School, Boston, MA, United StatesHarvard Medical School, Boston, MA, United StatesNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, AustraliaCancer Care Service, Mater Hospital, North Sydney, NSW, AustraliaFaculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaIncreasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “chemotherapy” and “microbiome/microbiota”. The relevant literature was selected for use in this article. Seventeen studies were selected on participants with colorectal cancer (CRC; n=5), Acute Myeloid Leukemia (AML; n=3), Non-Hodgkin’s lymphoma (n=2), breast cancer (BCa; n=1), lung cancer (n=1), ovarian cancer (n=1), liver cancer (n=1), and various other types of cancers (n=3). Seven studies assessed the relationship between the gut microbiome and CTX with faecal samples collected prior to (n=3) and following CTX (n=4) showing that the gut microbiome is associated with both CTX efficacy and toxicity. Ten other prospective studies assessed the impact of CTX during treatment and found that CTX modulates the gut microbiome of people with cancer and that dysbiosis induced by the CTX is related to AEs. CTX adversely impacts the gut microbiome, inducing dysbiosis and is associated with CTX outcomes and AEs. Current evidence provides insights into the gut microbiome for clinicians, cancer survivors and the general public. More research is required to better understand and modify the impact of CTX on the gut microbiome.https://www.frontiersin.org/articles/10.3389/fonc.2021.706331/fullgut microbiomechemotherapycancerbiomarkeradverse events